DISC-0974 Market Summary

Key Factors Driving DISC-0974 Growth

1. First-in-class anti-hemojuvelin (HJV) mechanism addresses a major unmet need in myelofibrosis-associated anemia

DISC-0974 is a first-in-class monoclonal antibody targeting hemojuvelin (HJV), a key upstream regulator of hepcidin, the master hormone controlling iron homeostasis. Elevated hepcidin contributes significantly to anemia in myelofibrosis (MF) and other inflammatory disorders by restricting iron availability for erythropoiesis. By inhibiting HJV, DISC-0974 suppresses hepcidin production, increases circulating iron, and promotes red blood cell production through a mechanism distinct from erythropoiesis-stimulating agents (ESAs) or JAK inhibitors. This novel biology positions DISC-0974 to address a substantial unmet need in MF patients, many of whom experience treatment-limiting anemia.

2. Encouraging Phase Ib/II clinical data demonstrate meaningful hematologic responses

Clinical data presented at the 2023 American Society of Hematology (ASH) Annual Meeting and updated in 2024 showed robust biological and clinical activity. DISC-0974 produced dose-dependent reductions in serum hepcidin exceeding 75% and corresponding >75% increases in serum iron at the 28 mg dose. Among evaluable non-transfusion-dependent MF patients treated at the 28–50 mg dose levels, 57% achieved a hemoglobin increase of >1.5 g/dL. Updated 2024 results further demonstrated that 68.9% of non-transfusion-dependent patients achieved a hemoglobin response ≥1.5 g/dL, while one transfusion-dependent patient became transfusion independent and all evaluable transfusion-dependent patients experienced at least a 50% reduction in transfusion requirements. These findings strongly support continued development.

3. Potential to complement existing JAK inhibitor therapy

Anemia remains one of the principal limitations of current JAK inhibitors such as ruxolitinib, with many patients requiring dose reductions or discontinuation because of worsening cytopenias. DISC-0974 is being evaluated in patients both receiving and not receiving concomitant JAK inhibitors, offering the potential to improve anemia without compromising MF disease control. Updated clinical data showed hemoglobin responses in patients receiving concurrent JAK inhibitor therapy, supporting its potential use as an add-on treatment rather than a replacement for existing standard therapies. This complementary positioning could significantly broaden its commercial opportunity.

4. Expansion into multiple anemia indications increases long-term market potential

Beyond myelofibrosis, Disc Medicine is evaluating DISC-0974 in non-dialysis-dependent chronic kidney disease (NDD-CKD)-associated anemia, another condition driven by elevated hepcidin levels. The company has stated that suppression of the HJV–hepcidin pathway could be applicable across several chronic inflammatory anemias, substantially expanding the drug's addressable market beyond the relatively small MF population. This lifecycle strategy diversifies development risk while creating opportunities for future label expansion.

5. Advancing toward late-stage development with favorable regulatory outlook

Disc Medicine has identified DISC-0974 as one of its core pipeline assets. According to the company's recent development update, the ongoing Phase II study in MF-associated anemia is expected to generate topline data in 2026, and positive results could support discussions with regulatory authorities regarding a registrational development pathway. Progression into pivotal studies would substantially de-risk the program and increase its commercial attractiveness.

DISC-0974 Recent Developments

In June 2026, Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, presented updated data from the RALLY-MF Phase II trial of DISC-0974 in anemia of MF at the ASCO Annual Meeting in Chicago, IL. In this updated data set, treatment with DISC-0974 shows substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types.

“DISC-0974 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of DISC-0974 for potential indication like Inflammatory bowel diseases and Anaemia in the 7MM. A detailed picture of DISC-0974’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the DISC-0974 for potential indications. The DISC-0974 market report provides insights about DISC-0974’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current DISC-0974 performance, future market assessments inclusive of the DISC-0974 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of DISC-0974 sales forecasts, along with factors driving its market.

DISC-0974 Drug Summary

DISC-0974 is an investigational, subcutaneously administered humanized monoclonal antibody targeting hemojuvelin (HJV) that is being developed for the treatment of anemia associated with myelofibrosis and other disorders characterized by ineffective erythropoiesis and iron-restricted anemia. DISC-0974 works by binding to hemojuvelin, a key regulator of the bone morphogenetic protein (BMP)/SMAD signaling pathway, thereby suppressing hepatic hepcidin production, increasing iron availability for erythropoiesis, and improving red blood cell production. Administered by subcutaneous injection, DISC-0974 is being evaluated in early-phase clinical trials both as a monotherapy and in combination with standard treatments, with preliminary data demonstrating increases in hemoglobin levels, reductions in transfusion requirements, and favorable pharmacodynamic effects on iron metabolism in patients with myelofibrosis-related anemia. The therapy has generally shown an acceptable safety profile to date, with most reported adverse events being mild to moderate, including injection-site reactions and transient laboratory abnormalities. Although not yet approved by regulatory authorities, DISC-0974 represents a promising novel approach to addressing anemia in myelofibrosis by targeting iron homeostasis rather than directly inhibiting malignant cell proliferation. The report provides DISC-0974’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the DISC-0974 Market Report

The report provides insights into:

• A comprehensive product overview including the DISC-0974 MoA, description, dosage and administration, research and development activities in potential indication like Inflammatory bowel diseases and Anaemia.
• Elaborated details on DISC-0974 regulatory milestones and other development activities have been provided in DISC-0974 market report.
• The report also highlights DISC-0974‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The DISC-0974 market report also covers the patents information, generic entry and impact on cost cut.
• The DISC-0974 market report contains current and forecasted DISC-0974 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The DISC-0974 market report also features the SWOT analysis with analyst views for DISC-0974 in potential indications.

Methodology

The DISC-0974 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DISC-0974 Analytical Perspective by DelveInsight

• In-depth DISC-0974 Market Assessment

This DISC-0974 sales market forecast report provides a detailed market assessment of DISC-0974 for potential indication like Inflammatory bowel diseases and Anaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted DISC-0974 sales data uptil 2034.

• DISC-0974 Clinical Assessment

The DISC-0974 market report provides the clinical trials information of DISC-0974 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

DISC-0974 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

DISC-0974 Market Potential & Revenue Forecast

• Projected market size for the DISC-0974 and its key indications
• Estimated DISC-0974 sales potential (DISC-0974 peak sales forecasts)
• DISC-0974 Pricing strategies and reimbursement landscape

DISC-0974 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• DISC-0974 Market positioning compared to existing treatments
• DISC-0974 Strengths & weaknesses relative to competitors

DISC-0974 Regulatory & Commercial Milestones

• DISC-0974 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

DISC-0974 Clinical Differentiation

• DISC-0974 Efficacy & safety advantages over existing drugs
• DISC-0974 Unique selling points

DISC-0974 Market Report Highlights

• In the coming years, the DISC-0974 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The DISC-0974 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DISC-0974’s dominance.
• Other emerging products for Inflammatory bowel diseases and Anaemia are expected to give tough market competition to DISC-0974 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DISC-0974 in potential indications.
• Analyse DISC-0974 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted DISC-0974 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of DISC-0974 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of DISC-0974? How strong is DISC-0974’s clinical and commercial performance?
• What is DISC-0974’s clinical trial status in each individual indications such as Inflammatory bowel diseases and Anaemia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DISC-0974 Manufacturers?
• What are the key designations that have been granted to DISC-0974 for potential indications? How are they going to impact DISC-0974’s penetration in various geographies?
• What is the current and forecasted DISC-0974 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of DISC-0974 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to DISC-0974 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is DISC-0974? What is the duration of therapy and what are the geographical variations in cost per patient?